Liang et al described the Systemic Lupus Activity Measure (SLAM) to assess lupus disease activity. It consists of 24 clinical and 7 laboratory measures. It was derived in Boston based on consensus of Lupus Council from the American College of Rheumatology.
Clinical parameters (24) :
(A) Constitutional
(1) weight loss
(2) fatigue
(3) fever
(B) Integument
(4) oral/nasal ulcer, periungal erythema, malar rash, photosensitivity, nail fold infarct
(5) alopecia
(6) erythematous, maculopapular rash or DLE, or lupus profundus or bullae
(7) vasculitis
(C) Eye
(8) cytoid bodies
(9) hemorrhage (retinal or choroidal) or episcleritis
(10) papillitis or pseudotumor cerebri
(D) Reticuloendothelial
(11) lymphadenopathy
(12) hepato- or splenomegaly
(E) Pulmonary
(13) effusion/pleurisy
(14) pneumonitis
(F) Cardiovascular
(15) Raynaud's phenomenon
(16) hypertension
(17) carditis
(G) Gastrointestinal
(18) abdominal pain (serositis, ischemic bowel, pancreatitis)
(H) Neuromuscular
(19) stroke syndrome
(20) seizure
(21) cortical dysfunction
(22) headache (including migraine)
(23) myalgia/myositis
(I) Joints
(24) joint pain from synovitis or tenosynovitis
There is provision for a 25th clinical parameter for "other" measure (see under grading, below).
Laboratory measures (7):
(1) hematocrit
(2) WBC count
(3) lymphocytes
(4) platelet count
(5) ESR by Westergren method
(6) serum creatinine, or creatinine clearance
(7) urine sediment
Grading instructions:
(1) The finding should be attributable to SLE.
(2) The finding should have been present during the month prior to the examination date.
(3) The most severe finding during this period should be graded.
(4) A condition is listed as inactive or active. If active than it is assigned points based on intensity with 1 point for mild, 2 points for moderate and 3 points for severe.
(5) If a new clinical manifestation occurs within a numbered grouping, then an additional rating using the same scale should be placed under "other" (25th clinical parameter, above). This does not apply to laboratory test findings.
Parameter |
Finding |
Points |
---|---|---|
weight loss |
none |
0 |
|
mild-to-moderate (1-10%) |
1 |
|
severe (> 10%) |
3 |
fatigue |
none |
0 |
|
mild-to-moderate (no limit on activity) |
1 |
|
severe (functional limitation) |
3 |
fever |
none |
0 |
|
37.5 – 38.5°C |
1 |
|
> 38.5°C |
3 |
oral/nasal ulcer, periungal erythema, malar rash, photosensitivity, nail fold infarct |
absent |
0 |
|
present |
1 |
alopecia |
none |
0 |
|
with trauma |
1 |
|
spontaneous |
2 |
erythematous, maculopapular rash or DLE, or lupus profundus or bullae |
absent |
0 |
|
< 20% BSA |
1 |
|
20 – 50% BSA |
2 |
|
> 50% |
3 |
vasculitis (leukocytoclastic vasculitis, urticaria, palpable purpura, livedo reticularis, ulcer or panniculitis) |
none |
0 |
|
< 20% BSA |
1 |
|
20 – 50% BSA |
2 |
|
> 50% |
3 |
cytoid bodies |
absent |
0 |
|
present but mild |
1 |
|
visual acuity < 20/200 |
3 |
hemorrhages (retinal or choroidal) or episcleritis |
absent |
0 |
|
present but mild |
1 |
|
visual acuity < 20/200 |
3 |
papillitis or pseudotumor cerebri |
absent |
0 |
|
present but mild |
1 |
|
visual acuity < 20/200 |
3 |
lymphadenopathy |
none |
0 |
|
shotty |
1 |
|
> 1 x 1.5 cm |
2 |
hepatomegaly or splenomegaly |
none |
0 |
|
palpable on inspiration |
1 |
|
palpable without inspiration |
2 |
effusion and/or pleurisy |
absent |
0 |
|
shortness of breath or pain only with prompting, exam normal |
1 |
|
shortness of breath or pain with exercise, decreased breath sounds, dull lower lobes |
2 |
|
shortness of breath at rest, decreased breath sounds, dull middle and lower lobes |
3 |
pneumonitis |
none |
0 |
|
on X-ray only |
1 |
|
shortness of breath on exertion |
2 |
|
shortness of breath at rest |
3 |
Raynaud's |
absent |
0 |
|
present |
1 |
hypertension |
absent |
0 |
|
diastolic 90 – 104 mm Hg |
1 |
|
diastolic 105 – 115 mm Hg |
2 |
|
diastolic > 115 mm Hg |
3 |
carditis |
absent |
0 |
|
by ECG, rub or ECHO; no symptoms |
1 |
|
chest pain or arrhythmia |
2 |
|
myocarditis and hemodynamic compromise or arrhythmia |
3 |
abdominal pain (serositis, ischemic bowel, pancreatitis) |
none |
0 |
|
mild (complaint) |
1 |
|
moderate (limiting) |
2 |
|
severe (signs, ascites) |
3 |
stroke syndrome |
absent |
0 |
|
single TIA |
1 |
|
multiple TIA or mononeuritis multiplex, chorea, cranial neuropathy |
2 |
|
CVA/myelitis, retinal vascular occlusion |
3 |
seizure |
none |
0 |
|
1-2 months |
1 |
|
> 2 months |
2 |
|
status epilepticus |
3 |
cortical dysfunction |
none |
0 |
|
mild depression, personality disorder, or cognitive impairment |
1 |
|
severe depression, limiting cognitive impairment |
2 |
|
psychosis, dementia, coma |
3 |
headache (including migraine) |
none |
0 |
|
mild symptoms or transient neurological signs |
1 |
|
interferes with normal activities |
2 |
|
incapacitating, aseptic meningitis |
3 |
myalgia and/or myositis |
absent |
0 |
|
mild |
1 |
|
limits some activities |
2 |
|
incapacitating |
3 |
joint pain from synovitis or tenosynovitis |
absent |
0 |
|
arthralgias |
1 |
|
objective inflammation |
2 |
|
limited function |
3 |
hematocrit |
> 35% |
0 |
|
30-35% |
1 |
|
25 – 29.9% |
2 |
|
< 25% |
3 |
WBC count |
> 3,500 per µL |
0 |
|
2,000 – 3,500 per µL |
1 |
|
1,000 – 2,000 per µL |
2 |
|
< 1,000 per µL |
3 |
lymphocytes |
1,500 – 4,000 per µL |
0 |
|
1,000 – 1,499 per µL |
1 |
|
500 – 999 per µL |
2 |
|
< 500 per µL |
3 |
platelets |
> 150,000 per µL |
0 |
|
100,000 – 150,000 per µL |
1 |
|
50,000 – 99,999 per µL |
2 |
|
< 50,000 per µL |
3 |
ESR (Westergren method) |
< 25 mm/h |
0 |
|
25 – 50 mm/h |
1 |
|
51 – 75 mm/h |
2 |
|
> 75 mm/h |
3 |
serum creatinine or creatinine clearance |
0.5 – 1.3 mg/dL; 80-100% normal creatinine clearance |
0 |
|
1.4 – 2.0 mg/dL; 60-79% normal creatinine clearance |
1 |
|
2.1 – 4.0 mg/dL; 30-60% normal creatinine clearance |
2 |
|
> 4 mg/dL; < 30% normal creatinine clearance |
3 |
urine sediment |
normal |
0 |
|
6-10 RBC or WBC per hpf; or 1-3 granular casts per hpf; or 1-2+ proteinuria; or < 0.5 g/L per 24 hours urine protein |
1 |
|
11-25 RBC or WBC per hpf; or > 3 granular casts per hpf; or 3-4+ proteinuria; or 0.5 to 3.5 g/L per 24 hours urine protein |
2 |
|
>25 RBC or WBC per hpf; or > 4+ proteinuria; or > 3.5 g/L per 24 hours urine protein |
3 |
where:
• Weight loss overlaps at 10% in the original table.
• The hypertension values for mild and moderate overlap at 105. I adjusted mild to 90-104.
SLAM score =
= SUM(points for all of the parameters)
Interpretation:
• minimum score: 0
• maximum score: 85
• The higher the score the more severe and extensive the disease.
• The presence of severe symptoms may indicate the need for immunosuppression.
Purpose: To evaluate disease activity in a patient with SLE using the Systemic Lupus Activity Measure (SLAM).
Specialty: Immunology/Rheumatology
Objective: disease progression
ICD-10: M32,